<DOC>
	<DOCNO>NCT02554877</DOCNO>
	<brief_summary>The purpose study determine whether PF-06291874 effective treatment T2DM</brief_summary>
	<brief_title>A 12-week Study To Evaluate PF-06291874 Once Day Adults With T2DM Inadequately Controlled On Metformin</brief_title>
	<detailed_description>This randomize , double blind , stratify , placebo control , parallel group study conduct T2DM subject receive background metformin therapy . Subjects complete screening procedure determine eligibility , follow 8 week metformin stabilization period prior randomization . In addition , subject take OADs , combination metformin , undergo washout period , non metformin OAD medication temporarily discontinue duration trial . Following confirmation study eligibility criterion randomization , subject stratify 2 group base use concomitant statin therapy . Each stratum randomize across treatment group , number subject take concomitant statin therapy take statin therapy approximately balance across treatment group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Males nonchildbearing potential female age 18 ( minimum country specific age consent &gt; 18 ) 70 year , inclusive , screen visit ( V1 ) diagnosis T2DM ; Female subject childbearing potential 2 . Subjects stable dose metformin either alone combination one additional acceptable OAD 3 . HbA1c Screen Visit ( V1 ) , assess study specific central laboratory , 711 % metformin monotherapy ; 6.59.5 % dual combination therapy ( metformin plus 1 ) 1 . Diagnosis type 1 diabetes mellitus secondary form diabetes ; 2 . Fasting plasma glucose level &gt; 270 mg/dL ( 15.0 mmol/L ) screen run visit , ( assess study specific central laboratory ) confirm single repeat , deem necessary 3 . History myocardial infarction , unstable angina , arterial revascularization , stroke , New York Heart Association Functional Class III IV heart failure , transient ischemic attack within 6 month screen ; 4 . Any medical condition possibly affect study drug absorption ( eg , gastrectomy area intestinal resection , active inflammatory bowel disease pancreatic insufficiency 5 . Subjects creatinine clearance &lt; 60 mL/min determine Cockcroft Gault equation ( list ) use serum creatinine measure screening , confirm via single repeat , deem necessary 6 . Subject positive result hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBc Ab ) hepatitis C virus ( HCV ) antibodies 7 . Screening seat systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 105 mm Hg least 5 minute rest . Blood pressure determine mean triplicate measurement collect approximately 2 minute rest measurement 8 . Screening supine 12 lead ECG demonstrating correct QT ( QTc ) &gt; 470 msec ; QRS interval &gt; 120 msec . If QTc exceed 470 msec QRS exceed 120 msec , ECG may repeat 2 time interval 24 minute measurement mean 3 value use determine subject 's eligibility 9 . Subjects arm circumference &gt; 52 cm measure midpoint length upper arm ; 10 . History ( within last 6 month ) regular alcohol consumption exceed 14 drink per week men 7 drink week woman . ( 1 drink = 5 ounce wine ( 150 mL ) 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) ; 11 . Treatment thiazolidinediones ( TZDs ) , subcutaneously administer anti diabetic agent ( eg , insulin , exenatide , liraglutide , pramlintide ) within 6 week prior V1 ; 12 . Subjects know hypersensitivity intolerance glucagon receptor antagonist , know prior participation trial involve PF 06291874 ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>